Skip to main content
Premium Trial:

Request an Annual Quote

Tepnel Raises $2.25M in Stock Offering to Help Pay for Scottish Consolidation

NEW YORK, June 2 (GenomeWeb News) - Tepnel Life Sciences has raised £1.2 million ($2.3 million) in a stock offering, the UK-based company said today.

The funds will be used as "working capital" and also to complete the company's new 18,000-square-foot facility in Livingston, Scotland. The new facility will consolidate operations in Edinburgh and Glasgow and incorporate pharmaceutical services including high throughput genotyping and protein analysis.

The company placed 17,034,160 new ordinary shares priced at 7p apiece with institutional shareholders. In addition, the company has given its investors warrantes to buy as many as 4.3 million additional shares. Tepnel expects stands to gain approximately £340,000 if all the shares are purchased in the warrant.

Tepnel applied to have the shares available for trading on the London Stock Exchange's AIM market on June 6.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.